FOSUN HEALTH Logo

Multiple Myeloma Prevention

catalogue

Multiple Myeloma Prevention

Multiple Myeloma Prevention

Multiple myeloma cannot be prevented, and there is no screening test that would find it in someone without symptoms. That is not a failure of effort — it is a consequence of the disease being uncommon, of its precursor being common without progressing, and of treatment for the precursor having no demonstrated benefit. What does exist is monitoring for people in whom a monoclonal protein has already been found, and a set of concrete measures that protect the two organs myeloma damages. Those measures are worth taking seriously, because unlike most prevention advice they change something real.

Why there is no screening test

Patients reasonably ask why a disease that is measurable in a blood test is not screened for. The answer is a specific one, and it is worth stating in full because it explains a great deal about how the disease is managed:

  • Precursors are far commoner than the disease. A monoclonal protein is found in a substantial proportion of older adults, and most of those people never develop myeloma. Testing everyone would identify a large number of people who would never have become ill.
  • Finding a precursor early has not been shown to change the outcome. The reason is that no treatment has been shown to improve survival when given to a precursor that has caused no damage; treating it would expose people to side effects for no demonstrated benefit.
  • Treatment is triggered by damage rather than by the test. This is unusual and it is deliberate: the disease is treated when it has caused, or is about to cause, organ damage — which is why the defining events rather than the diagnosis alone start treatment.
  • A normal blood test does not exclude it. Early disease can be present with a nearly normal count, and a monoclonal protein can be missed on routine testing if electrophoresis is not performed. So a normal result should not be used to dismiss persistent symptoms.

Monitoring a known monoclonal protein

The one situation in which the disease is genuinely detected early is when a monoclonal protein has been found — most often on a blood test taken for an unrelated reason. That finding triggers, in effect, a personal screening programme:

  • A full assessment at the outset — repeat protein measurement with immunofixation, the light chain ratio, a blood count, calcium, creatinine and albumin, and imaging of the skeleton, so that the baseline is documented rather than assumed.
  • An interval set by the findings — a small protein with a normal blood count is usually checked at longer intervals, whereas a larger protein or a borderline blood count warrants closer monitoring.
  • What triggers closer investigation — a rising protein level, a falling haemoglobin or platelet count, a rising calcium, deteriorating kidney function, a new bone symptom, or any of the three laboratory thresholds described on the overview page.
  • The purpose is timing, not prevention — the aim is to begin treatment at the point where it helps, which is generally when damage appears, and to avoid both treating too early and discovering it too late.
  • A definite plan with dates — when the next test is due, what will be measured, and who to contact if symptoms appear between visits.

The exposures that can be limited

The avoidable share of the risk is small, and it is worth being honest about that rather than offering measures with no evidence behind them:

  • Radiation exposure is cumulative and partly controllable. No necessary imaging should be avoided, but unnecessary scans should not be requested. This is a reasonable principle rather than a claim that diagnostic imaging causes myeloma, which it has not been shown to do.
  • Occupational protection — for anyone working with pesticides, herbicides or organic solvents, the measures that reduce exposure are worth following, and they are required in most settings. There is no test that would show whether exposure has had an effect.
  • Stopping smoking is still worth doing — not because smoking causes myeloma, for which the evidence is not sufficient, but because it causes several other cancers and increases the risks of treatment and infection.
  • What not to do — no supplement, dietary restriction or alternative treatment has been shown to prevent myeloma, and some interact with treatment. Ask before adding anything.

Protecting bone and kidney

This is where preventive measures actually change something. Myeloma does its damage to bone and kidney, and both are affected by ordinary decisions that a patient can make:

  • Avoid anti-inflammatory painkillers — ibuprofen, diclofenac, naproxen and similar drugs reduce blood flow through the kidney and can precipitate injury in a disease that already threatens it. Paracetamol is usually the safer choice for pain, and any new pain medicine should be discussed.
  • Keep drinking enough fluid — hydration protects the kidney, particularly during treatment, during periods of vomiting or diarrhoea, and in hot weather.
  • Correct calcium and vitamin D where they are low, and use bone-strengthening medication as prescribed; a dental review is arranged before it starts, because complications of the jaw are far easier to prevent than to treat.
  • Stay current with vaccination — influenza, pneumococcal disease, shingles and the standard vaccine schedule, adjusted for treatment. Live vaccines are avoided during and for a period after treatment.
  • Treat pain on a schedule rather than on demand, and think about falls — removing trip hazards, using a stick if balance is affected, and keeping up gentle activity rather than becoming inactive, since inactivity weakens both bone and muscle.
  • Ask about prophylactic antibiotics and clot prevention, which are used routinely during parts of treatment and are a reason for scheduled rather than symptom-driven review.

What prevention cannot do

An honest account of the limits is more useful than optimism, and in this disease the limits are specific:

  • It cannot prevent the disease. No intervention has been shown to stop a monoclonal gammopathy from progressing, which is why observation rather than treatment is the approach.
  • It cannot replace treatment once damage has occurred — no dietary or lifestyle measure substitutes for treating active disease, and deferring treatment in favour of such measures has a cost.
  • It cannot undo existing bone loss completely — bone-strengthening treatment reduces the risk of further fractures and further loss, but a bone that has already collapsed cannot be restored to its previous state.
  • It cannot make monitoring unnecessary — the tests are what detect a change before symptoms do, and the most common reason for a difficult situation is a gap in monitoring rather than a failure of treatment.
  • And a normal test does not provide certainty — if symptoms are persistent, they should be assessed even if recent results were reassuring, because the answers change what happens next.

What follow-up looks like

Whether a patient is being monitored for a precursor or followed after treatment, the follow-up has a defined structure, and knowing it makes the process manageable:

  • During monitoring for a precursor — the protein level with the light chain ratio, a blood count, calcium and creatinine at intervals set by the baseline findings, with imaging only when there is a new symptom or a change in the results.
  • During treatment — the same measurements at each cycle, because the depth of the response decides what is given next, together with kidney function and blood counts to guide doses.
  • After the intensive phase — the protein and light chain ratio at widening intervals, with bone imaging or a marrow examination if the numbers suggest a change, and continued vaccination and infection precautions.
  • What to report between visits — new or worsening bone pain, especially with weakness or numbness in the legs; confusion, thirst or passing large volumes of urine; a fever during treatment; reduced urine output; or numbness and tingling in the feet.
  • Keeping the record — the values with their units and dates, the drug names and cumulative doses, and the chromosome findings from the original marrow. In a disease followed over years, a patient-held record is often the most complete document in the room.

Frequently Asked Questions

Should I be tested for myeloma if a relative has it?

No. A first-degree relative with myeloma modestly increases your risk compared with the general population, but no monitoring programme or genetic test is recommended on that basis alone, because the increase is small and because no treatment has been shown to help when the disease is found at a stage that causes no damage. What is worth doing is mentioning the family history if you ever have a blood test that is unexplained, and having persistent bone pain, anaemia or a change in kidney function assessed rather than attributed to age.

Is there anything I can do to stop MGUS becoming myeloma?

There is no measure — dietary, lifestyle, supplement or medical — that has been shown to stop a monoclonal gammopathy from progressing, and this is why the approach is monitoring rather than treatment. What you can do is keep the monitoring appointments, know what your baseline values were so that changes are recognised, avoid the medicines that harm the kidney, and report new bone pain or unexplained symptoms between visits. If progression occurs, it is usually detected by the tests rather than by symptoms, and that is the point of the schedule.

How often should the tests be repeated?

The interval is set by the findings rather than by a fixed rule. A small monoclonal protein with a normal blood count, normal calcium and normal kidney function is generally checked at longer intervals; a larger protein, a borderline blood count or a higher-risk chromosome finding warrants closer monitoring. After treatment, the protein and light chain ratio are measured frequently at first and then at widening intervals. The specific schedule for your case, with dates, should be written down and given to you — ask for it rather than leaving the interval to be inferred.

Do I need to avoid any particular food or activity?

No food has been shown to affect the course of the disease. During treatment, food safety matters — avoiding unpasteurised dairy, raw or undercooked meat, eggs and seafood and unwashed produce — because infection is the risk, not the food itself. Activity should be encouraged rather than restricted, within what painful bone lesions allow; a physiotherapy assessment helps to combine safety with maintaining strength and balance, which is the most effective way to reduce the chance of a fracture.

Ask what your monitoring interval should be

Send the most recent monoclonal protein measurement with its units and date, the light chain ratio, the blood count, calcium and creatinine, the plasma cell proportion from the marrow if it has been taken, and any bone imaging. Our haematology team will return a written assessment within 48 hours of the file being complete, including whether monitoring or treatment is appropriate and at what interval.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*